search
Back to results

A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours (BrainStorm)

Primary Purpose

CNS Metastases

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Samples collection: Plasma
Samples collection: CSF
Samples collection: Non-CNS Metastatic Tumour Tissue
Brain MRI
Samples collection: Serum
Sponsored by
Jules Bordet Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for CNS Metastases

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age ≥ 18 years old
  2. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  3. Female or Male

  4. Eligible for part A: Subjects (from cohorts 1 to 5) with newly diagnosed or up to 24 months from diagnosis of non-CNS metastases. Enrolment of exceptional cases surpassing 24 months from diagnosis will be allowed for up to 20% of subjects enrolled with HER2+ BC (cohort 2) and NSCLC harbouring driver mutations (cohort 3).

    Eligible for part B: Subjects (from cohorts 1 to 7) presenting with a first CNS event and not yet enrolled in the program

    Seven cohorts of subjects are defined in this prospective multicenter study:

    • Cohort 1: Triple negative breast cancer (TNBC)
    • Cohort 2: HER 2 positive breast cancer (HER2+ BC)
    • Cohort 3: Non-small cell lung cancer (NSCLC)
    • Cohort 4: Small cell lung cancer (SCLC)
    • Cohort 5: Melanoma
    • Cohort 6: Other solid tumours (apart from the above mentioned subtypes
    • Cohort 7: Radiologically or cytologically confirmed leptomeningeal carcinomatosis
  5. Availability of either primary and/or non-CNS metastatic archival tumour tissue is mandatory for inclusion.
  6. Willingness to undergo lumbar puncture at diagnosis of CNS metastases unless medical contra-indications
  7. Predicted life expectancy > 3 months.
  8. Women of childbearing potential must have a negative urine pregnancy test done within 28 days prior to enrolment
  9. Effective contraception is in place for women of childbearing potential
  10. Completion of all necessary screening procedures within 28 days prior to enrolment.

  11. Signed Informed Consent form (ICF) obtained prior to any study related procedure.

    Inclusion criterion applicable to FRANCE only

  12. Affiliated to the French Social Security System

Exclusion Criteria:

  1. Pregnant and/or lactating women.
  2. Previous or current malignancies of other histologies within the last 2 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin.

  3. Subject with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator's opinion, may interfere with completion of the study.

    Exclusion criterion applicable to FRANCE only

  4. Vulnerable persons according to the article L.1121-6 of the Public Health Code, adults who are the subject of a measure of legal protection or unable to express their consent according to article L.1121-8 of the Public Health Code.

Sites / Locations

  • Institut Jules BordetRecruiting
  • Hôpital ErasmeRecruiting
  • Cliniques Universitaires St LucRecruiting
  • Grand Hôpital de CharleroiRecruiting
  • Universitair Ziekenhuis GentRecruiting
  • UZ BrusselRecruiting
  • UZ LeuvenRecruiting
  • CHU Ambroise ParéRecruiting
  • CHU UCL Namur - Site de Sainte-ElisabethRecruiting
  • Centre Oscar LambretRecruiting
  • Institut Paoli-CalmettesRecruiting
  • Institut Universitaire de Cancérologie AP-HP Sorbonne Université, Hopital TenonRecruiting
  • Institut CurieRecruiting
  • Centre Henri BecquerelRecruiting
  • CHU StrasbourgRecruiting
  • Institut Universitaire du Cancer - OncopoleRecruiting
  • Centre Hospitalier de LuxembourgRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

CNS metastases from solid tumours

Arm Description

The study will be organised on three time-periods based on the time of the 1st CNS event: Part A - Pre-diagnosis period: before diagnosis of the 1st CNS event Part B - At 1st CNS diagnosis period Part C - Post diagnosis period: after the 1st CNS event

Outcomes

Primary Outcome Measures

Better understanding of the epidemiology of CNS metastases from solid tumours
To collect data regarding the epidemiology of CNS metastases from solid tumours and identify risk factors for CNS metastases development, including: Time to the first CNS event Time to the second CNS after first treatment and subsequent CNS events
Better understanding of the epidemiology of CNS metastases from solid tumours
To collect data regarding the epidemiology of CNS metastases from solid tumours and identify risk factors for CNS metastases development, including:: - Time to whole brain radiotherapy
Better understanding of the epidemiology of CNS metastases from solid tumours
To collect data regarding the epidemiology of CNS metastases from solid tumours and identify risk factors for CNS metastases development, including: - Overall survival
Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.
To collect data regarding the biology of CNS metastases by investigating on: - Presence of CSF-ctDNA at diagnosis of CNS metastases
Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.
To collect data regarding the biology of CNS metastases by investigating on: - Presence of plasma ctDNA at diagnosis of CNS metastases
Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.
quantification of plasma ctDNA and CSF-ctDNA using deep targeted NGS deep targeted next-generation sequencing (NGS) on DNA samples from primary or non-CNS metastases as well as germline DNA samples and CNS metastases if surgery
Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.
- A set of 1-3 point mutations (single nucleotide variants) will be selected for each subject based on the above analyses for the identification and quantification of plasma ctDNA and CSF-ctDNA using deep targeted NGS
Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.
- Standard analyses cytology and biochemistry analyses
Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.
- Quantitative measurement of serum neuron-specific enolase

Secondary Outcome Measures

Full Information

First Posted
July 12, 2019
Last Updated
March 27, 2023
Sponsor
Jules Bordet Institute
Collaborators
La Fondation contre le cancer, Belgique, Les Amis de l'Institut Bordet, Bristol-Myers Squibb, Fondation Cancer, Luxembourg
search

1. Study Identification

Unique Protocol Identification Number
NCT04109131
Brief Title
A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours
Acronym
BrainStorm
Official Title
A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours - BrainStorm Program
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 1, 2020 (Actual)
Primary Completion Date
January 2027 (Anticipated)
Study Completion Date
January 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jules Bordet Institute
Collaborators
La Fondation contre le cancer, Belgique, Les Amis de l'Institut Bordet, Bristol-Myers Squibb, Fondation Cancer, Luxembourg

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Despite some encouraging data, systemic treatment of CNS metastases from solid tumors remains experimental. Better knowledge on the evolving epidemiology and biology of BM are key elements for the development of new treatment strategies and identification of promising therapeutic targets for new compounds. Further biological findings may help to better understand the heterogeneity between the primary tumor and the CNS metastases and to identify new targets for therapy thus improving patients' outcome. In this context, the Oncodistinct network and the Jules Bordet institute propose to build a multidisciplinary Brain Metastases Clinical Research Platform called BrainStorm. The BrainStorm program will focus on patients with newly diagnosed non-CNS metastatic solid tumors with high risk of developing CNS metastases and will allow building a large clinico pathological database for CNS metastases including ctDNA analyzes from CSF samples. Substudies will be proposed at each time-period with the final objective to develop innovative treatment approaches and strategies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
CNS Metastases

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
600 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
CNS metastases from solid tumours
Arm Type
Other
Arm Description
The study will be organised on three time-periods based on the time of the 1st CNS event: Part A - Pre-diagnosis period: before diagnosis of the 1st CNS event Part B - At 1st CNS diagnosis period Part C - Post diagnosis period: after the 1st CNS event
Intervention Type
Other
Intervention Name(s)
Samples collection: Plasma
Other Intervention Name(s)
Blood for plasma preparation
Intervention Description
At baseline Part A: TNBC/ HER2+ BC: once a year NSCLC/SCLC: every 4 months Melanoma: every 6 months Part B: o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis Part C: o Every 3 months (+/- 1 month)
Intervention Type
Other
Intervention Name(s)
Samples collection: CSF
Other Intervention Name(s)
CSF sample
Intervention Description
Part B: Mandatory CSF sampling at CNS diagnosis when clinically possible unless medically contra-indicated - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis Part C: Additional CSF sampling in case CSF sampling is performed for routine clinical practice
Intervention Type
Other
Intervention Name(s)
Samples collection: Non-CNS Metastatic Tumour Tissue
Other Intervention Name(s)
Non-CNS Metastatic Tumour Tissue collection
Intervention Description
Part B: Highly recommended non-CNS metastatic tumour tissue collection (1FFPE and 1 FT) at CNS metastases diagnosis (Part B) (NB: Bone lesions are excluded) - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis
Intervention Type
Other
Intervention Name(s)
Brain MRI
Intervention Description
Part A: Brain MRI at inclusion is allowed within 45 days before enrolment Brain MRI pre-CNS diagnosis (Part A) : HER2 BC/TNBC: once a year; NSCLC/SCLC: every 4 months; Melanoma: every 6 months (+/- 1 month) Part B: o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis Part C: o Brain MRI post-CNS diagnosis (Part C): every 3 months (+/- 1 month window)
Intervention Type
Other
Intervention Name(s)
Samples collection: Serum
Other Intervention Name(s)
Blood for serum preparation
Intervention Description
At baseline Part A: TNBC/ HER2+ BC: once a year NSCLC/SCLC: every 4 months Melanoma: every 6 months Part B: o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis for cohorts 1-5.
Primary Outcome Measure Information:
Title
Better understanding of the epidemiology of CNS metastases from solid tumours
Description
To collect data regarding the epidemiology of CNS metastases from solid tumours and identify risk factors for CNS metastases development, including: Time to the first CNS event Time to the second CNS after first treatment and subsequent CNS events
Time Frame
through study completion, approximately 96 months
Title
Better understanding of the epidemiology of CNS metastases from solid tumours
Description
To collect data regarding the epidemiology of CNS metastases from solid tumours and identify risk factors for CNS metastases development, including:: - Time to whole brain radiotherapy
Time Frame
through study completion, approximately 96 months
Title
Better understanding of the epidemiology of CNS metastases from solid tumours
Description
To collect data regarding the epidemiology of CNS metastases from solid tumours and identify risk factors for CNS metastases development, including: - Overall survival
Time Frame
through study completion, approximately 96 months
Title
Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.
Description
To collect data regarding the biology of CNS metastases by investigating on: - Presence of CSF-ctDNA at diagnosis of CNS metastases
Time Frame
through study completion, approximately 96 months
Title
Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.
Description
To collect data regarding the biology of CNS metastases by investigating on: - Presence of plasma ctDNA at diagnosis of CNS metastases
Time Frame
through study completion, approximately 96 months
Title
Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.
Description
quantification of plasma ctDNA and CSF-ctDNA using deep targeted NGS deep targeted next-generation sequencing (NGS) on DNA samples from primary or non-CNS metastases as well as germline DNA samples and CNS metastases if surgery
Time Frame
through study completion, approximately 96 months
Title
Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.
Description
- A set of 1-3 point mutations (single nucleotide variants) will be selected for each subject based on the above analyses for the identification and quantification of plasma ctDNA and CSF-ctDNA using deep targeted NGS
Time Frame
through study completion, approximately 96 months
Title
Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.
Description
- Standard analyses cytology and biochemistry analyses
Time Frame
through study completion, approximately 96 months
Title
Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.
Description
- Quantitative measurement of serum neuron-specific enolase
Time Frame
through study completion, approximately 96 months
Other Pre-specified Outcome Measures:
Title
Better understand the predictive value of NSE for the development of CNS metastases on subjects with newly diagnosed non-CNS metastatic solid tumours with high risk of developing CNS metastases.
Description
To collect data regarding the biology of CNS metastases by investigating on : Time to the first CNS event Time to the second CNS event Time to whole brain radiotherapy (WBR) Time from the date of diagnosis of the first CNS event and the time of death by any cause
Time Frame
through study completion, approximately 96 months
Title
Better understand the predictive value of NSE for the development of CNS metastases on subjects with newly diagnosed non-CNS metastatic solid tumours with high risk of developing CNS metastases.
Description
Levels of neuron specific enolase in blood
Time Frame
through study completion, approximately 96 months
Title
Better understand the predictive value of NSE for the development of CNS metastases on subjects with newly diagnosed non-CNS metastatic solid tumours with high risk of developing CNS metastases.
Description
Deep targeted next-generation sequencing (NGS) on DNA samples from primary or non CNS metastases as well as germline DNA samples and CNS metastases if surgery. A set of 1-3 point mutations (single nucleotide variants) will be selected for each subject based on the above analyses for the identification and quantification of plasma ctDNA and CSF-ctDNA using deep targeted NGS. Subsequently targeted gene sequencing will be performed on DNA samples from CSF and plasma in case of at least 5% tumour mutant allele frequency (MAF) and CNS metastases in case of surgery.
Time Frame
through study completion, approximately 96 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years old Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 Female or Male Eligible for part A: Subjects (from cohorts 1 to 5) with newly diagnosed or up to 24 months from diagnosis of non-CNS metastases. Enrolment of exceptional cases surpassing 24 months from diagnosis will be allowed for up to 20% of subjects enrolled with HER2+ BC (cohort 2) and NSCLC harbouring driver mutations (cohort 3). Eligible for part B: Subjects (from cohorts 1 to 7) presenting with a first CNS event and not yet enrolled in the program Seven cohorts of subjects are defined in this prospective multicenter study: Cohort 1: Triple negative breast cancer (TNBC) Cohort 2: HER 2 positive breast cancer (HER2+ BC) Cohort 3: Non-small cell lung cancer (NSCLC) Cohort 4: Small cell lung cancer (SCLC) Cohort 5: Melanoma Cohort 6: Other solid tumours (apart from the above mentioned subtypes Cohort 7: Radiologically or cytologically confirmed leptomeningeal carcinomatosis Availability of either primary and/or non-CNS metastatic archival tumour tissue is mandatory for inclusion. Willingness to undergo lumbar puncture at diagnosis of CNS metastases unless medical contra-indications Predicted life expectancy > 3 months. Women of childbearing potential must have a negative urine pregnancy test done within 28 days prior to enrolment Effective contraception is in place for women of childbearing potential Completion of all necessary screening procedures within 28 days prior to enrolment. Signed Informed Consent form (ICF) obtained prior to any study related procedure. Inclusion criterion applicable to FRANCE only Affiliated to the French Social Security System Exclusion Criteria: Pregnant and/or lactating women. Previous or current malignancies of other histologies within the last 2 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin. Subject with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator's opinion, may interfere with completion of the study. Exclusion criterion applicable to FRANCE only Vulnerable persons according to the article L.1121-6 of the Public Health Code, adults who are the subject of a measure of legal protection or unable to express their consent according to article L.1121-8 of the Public Health Code.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nuria Kotecki
Phone
+322541
Ext
7366
Email
nuria.kotecki@bordet.be
First Name & Middle Initial & Last Name or Official Title & Degree
Diane Delaroche
Phone
+322541
Ext
7358
Email
diane.delaroche@bordet.be
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nuria Kotecki, MD
Organizational Affiliation
Jules Bordet Institute
Official's Role
Study Chair
Facility Information:
Facility Name
Institut Jules Bordet
City
Anderlecht
ZIP/Postal Code
1070
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sylvie Bartholomeus
First Name & Middle Initial & Last Name & Degree
Andrea Gombos
Facility Name
Hôpital Erasme
City
Brussels
ZIP/Postal Code
1070
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Véronique Goblet
Phone
+32 2 541 30 39
Email
Veronique.Goblet@erasme.ulb.ac.be
First Name & Middle Initial & Last Name & Degree
Florence Lefranc, MD
Facility Name
Cliniques Universitaires St Luc
City
Bruxelles
ZIP/Postal Code
1200
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nathalie Blondeel
First Name & Middle Initial & Last Name & Degree
François Duhoux
Facility Name
Grand Hôpital de Charleroi
City
Charleroi
ZIP/Postal Code
6000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Veronique Petre
First Name & Middle Initial & Last Name & Degree
Jean-Luc Canon
Facility Name
Universitair Ziekenhuis Gent
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lore Vansteelant
First Name & Middle Initial & Last Name & Degree
Hannelore Denys
Facility Name
UZ Brussel
City
Jette
ZIP/Postal Code
1090
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Malika Tahiri
First Name & Middle Initial & Last Name & Degree
Lore Decoster
Facility Name
UZ Leuven
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Inge Wauters
Email
ingeborg.wauters@uzleuven.be
First Name & Middle Initial & Last Name & Degree
Paul Clement, MD
Facility Name
CHU Ambroise Paré
City
Mons
ZIP/Postal Code
7000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna-Maria Barbuto
First Name & Middle Initial & Last Name & Degree
Stéphane Holbrechts
Facility Name
CHU UCL Namur - Site de Sainte-Elisabeth
City
Namur
ZIP/Postal Code
5000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dominique Crasson
First Name & Middle Initial & Last Name & Degree
Vincent Vanhaudenarde
Facility Name
Centre Oscar Lambret
City
Lille
ZIP/Postal Code
59020
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Solene Charpentier
Email
s-charpentier@o-lambret.fr
First Name & Middle Initial & Last Name & Degree
Claire Cheymol, MD
Facility Name
Institut Paoli-Calmettes
City
Marseille
ZIP/Postal Code
13273
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anthony Lombardi
Email
LOMBARDIA@ipc.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Anthony Goncalves, MD
Facility Name
Institut Universitaire de Cancérologie AP-HP Sorbonne Université, Hopital Tenon
City
Paris
ZIP/Postal Code
75020
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joseph Gligorov, MD
Email
joseph.gligorov@aphp.fr
Facility Name
Institut Curie
City
Paris
ZIP/Postal Code
75248
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Imen Hafsi
First Name & Middle Initial & Last Name & Degree
Edith Borcoman, MD
Facility Name
Centre Henri Becquerel
City
Rouen
ZIP/Postal Code
76038
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Delphine Bridelance
Email
delphine.bridelance@chb.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Florian Clatot, MD
Facility Name
CHU Strasbourg
City
Strasbourg
ZIP/Postal Code
67200
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sherine Anajar
First Name & Middle Initial & Last Name & Degree
Philippe Barthelemy, MD
Facility Name
Institut Universitaire du Cancer - Oncopole
City
Toulouse
ZIP/Postal Code
31059
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marina Basmaison
Email
Basmaison.Marina@iuct-oncopole.fr
First Name & Middle Initial & Last Name & Degree
Eleonora De Maio Desposito, MD
Facility Name
Centre Hospitalier de Luxembourg
City
Luxembourg
ZIP/Postal Code
1445
Country
Luxembourg
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chouaib Mediouni
Email
chouaib.mediouni@lih.lu
First Name & Middle Initial & Last Name & Degree
Caroline Duhem, MD

12. IPD Sharing Statement

Learn more about this trial

A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours

We'll reach out to this number within 24 hrs